MicroRNA-143 down-regulates Hexokinase 2 in colon cancer cells

BMC Cancer

Lea H Gregersen²  Anders Jacobsen¹  Lisa B Frankel⁴  Jiayu Wen³  Anders Krogh³  Anders H Lund⁴ 

[1] Computational Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

[2] Berlin Institute for Medical Systems Biology, Max-Delbrück-Center for Molecular Medicine, D-13125, Berlin, Germany

[3] The Bioinformatics Centre, Department of Biology, University of Copenhagen, DK-2200, Copenhagen N, Denmark

[4] Biotech Research and Innovation Centre and Centre for Epigenetics, University of Copenhagen, DK-2200, Copenhagen N, Denmark

关键词: Glycolysis;    Hexokinase 2;    Colon cancer;    miR-143;   

Others  :  1080375
DOI  :  10.1186/1471-2407-12-232

 received in 2011-10-25, accepted in 2012-05-15,  发布年份 2012

【 摘 要 】

Background

MicroRNAs (miRNAs) are well recognized as gene regulators and have been implicated in the regulation of development as well as human diseases. miR-143 is located at a fragile site on chromosome 5 frequently deleted in cancer, and has been reported to be down-regulated in several cancers including colon cancer.

Methods

To gain insight into the role of miR-143 in colon cancer, we used a microarray-based approach in combination with seed site enrichment analysis to identify miR-143 targets.

Results

As expected, transcripts down-regulated upon miR-143 overexpression had a significant enrichment of miR-143 seed sites in their 3'UTRs. Here we report the identification of Hexokinase 2 (HK2) as a direct target of miR-143. We show that re-introduction of miR-143 in the colon cancer cell line DLD-1 results in a decreased lactate secretion.

Conclusion

We have identified and validated HK2 as a miR-143 target. Furthermore, our results indicate that miR-143 mediated down-regulation of HK2 affects glucose metabolism in colon cancer cells. We hypothesize that loss of miR-143-mediated repression of HK2 can promote glucose metabolism in cancer cells, contributing to the shift towards aerobic glycolysis observed in many tumors.

【 授权许可】

   
2012 Gregersen et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1 .

Figure 2 .

Figure 3 .

Figure 4 .

【 参考文献 】

• [1]Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
• [2]Krol J, Loedige I, Filipowicz W: The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010, 11:597-610.
• [3]Fabian MR, Sonenberg N, Filipowicz W: Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem 2010, 79:351-379.
• [4]Flynt AS, Lai EC: Biological principles of microRNA-mediated regulation: shared themes amid diversity. Nat Rev Genet 2008, 9:831-842.
• [5]Ventura A, Jacks T: MicroRNAs and cancer: short RNAs go a long way. Cell 2009, 136:586-591.
• [6]Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, Shimizu M, Cimmino A, Zupo S, Dono M, et al.: MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A 2004, 101:11755-11760.
• [7]Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al.: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006, 103:2257-2261.
• [8]Garzon R, Calin GA, Croce CM: MicroRNAs in cancer. Annu Rev Med 2009, 60:167-179.
• [9]Esquela-Kerscher A, Slack FJ: Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer 2006, 6:259-269.
• [10]Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY: miR-21-mediated tumor growth. Oncogene 2007, 26:2799-2803.
• [11]He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, Hammond SM: A microRNA polycistron as a potential human oncogene. Nature 2005, 435:828-833.
• [12]Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004, 101:2999-3004.
• [13]Akao Y, Nakagawa Y, Kitade Y, Kinoshita T, Naoe T: Downregulation of microRNAs-143 and -145 in B-cell malignancies. Cancer Sci 2007, 98:1914-1920.
• [14]Akao Y, Nakagawa Y, Naoe T: MicroRNA-143 and -145 in colon cancer. DNA Cell Biol 2007, 26:311-320.
• [15]Chen X, Guo X, Zhang H, Xiang Y, Chen J, Yin Y, Cai X, Wang K, Wang G, Ba Y, et al.: Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 2009, 28:1385-1392.
• [16]Lui WO, Pourmand N, Patterson BK, Fire A: Patterns of known and novel small RNAs in human cervical cancer. Cancer Res 2007, 67:6031-6043.
• [17]Michael MZ, O’Connor SM, van Holst Pellekaan NG, Young GP, James RJ: Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 2003, 1:882-891.
• [18]Ng EK, Tsang WP, Ng SS, Jin HC, Yu J, Li JJ, Rocken C, Ebert MP, Kwok TT, Sung JJ: MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer. Br J Cancer 2009, 101:699-706.
• [19]Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T: MicroRNA expression profiling in prostate cancer. Cancer Res 2007, 67:6130-6135.
• [20]Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M, Nenutil R, Vyzula R: Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 2007, 72:397-402.
• [21]Wang CJ, Zhou ZG, Wang L, Yang L, Zhou B, Gu J, Chen HY, Sun XF: Clinicopathological significance of microRNA-31, -143 and -145 expression in colorectal cancer. Dis Markers 2009, 26:27-34.
• [22]Ugras S, Brill ER, Jacobsen A, Hafner M, Socci N, Decarolis PL, Khanin R, O'Connor RB, Mihailovic A, Taylor BS, et al.: Small RNA sequencing and functional characterization reveals microRNA-143 tumor suppressor activity in liposarcoma. Cancer Res 2011, 71:5659-5669.
• [23]Elia L, Quintavalle M, Zhang J, Contu R, Cossu L, Latronico MV, Peterson KL, Indolfi C, Catalucci D, Chen J, et al.: The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death Differ 2009, 16:1590-1598.
• [24]Esau C, Kang X, Peralta E, Hanson E, Marcusson EG, Ravichandran LV, Sun Y, Koo S, Perera RJ, Jain R, et al.: MicroRNA-143 regulates adipocyte differentiation. J Biol Chem 2004, 279:52361-52365.
• [25]Xie H, Lim B, Lodish HF: MicroRNAs induced during adipogenesis that accelerate fat cell development are downregulated in obesity. Diabetes 2009, 58:1050-1057.
• [26]Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, Muth AN, Lee TH, Miano JM, Ivey KN, Srivastava D: miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 2009, 460:705-710.
• [27]Gregersen LH, Jacobsen AB, Frankel LB, Wen J, Krogh A, Lund AH: MicroRNA-145 targets YES and STAT1 in colon cancer cells. PLoS One 2010, 5:e8836.
• [28]Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH: Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem 2008, 283:1026-1033.
• [29]Yuan S, Fu Y, Wang X, Shi H, Huang Y, Song X, Li L, Song N, Luo Y: Voltage-dependent anion channel 1 is involved in endostatin-induced endothelial cell apoptosis. FASEB J 2008, 22:2809-2820.
• [30]G Smyth: Limma: linear models for microarray data. In Bioinformatics and Computational Biology, Solutions using R and Bioconductor. Edited by Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W. Springer, New York; 2005:397-420.
• [31]Kanehisa M, Goto S: KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 2000, 28:27-30.
• [32]Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005, 102:15545-15550.
• [33]Luo W, Friedman MS, Shedden K, Hankenson KD, Woolf PJ: GAGE: generally applicable gene set enrichment for pathway analysis. BMC Bioinforma 2009, 10:161. BioMed Central Full Text
• [34]Jacobsen A, Wen J, Marks DS, Krogh A: Signatures of RNA binding proteins globally coupled to effective microRNA target sites. Genome Res 2010, 20:1010-1019.
• [35]Lewis MJ, Wiebe JP, Heathcote JG: Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma. BMC Cancer 2004, 4:27. BioMed Central Full Text
• [36]Ajiro M, Katagiri T, Ueda K, Nakagawa H, Fukukawa C, Lin ML, Park JH, Nishidate T, Daigo Y, Nakamura Y: Involvement of RQCD1 overexpression, a novel cancer-testis antigen, in the Akt pathway in breast cancer cells. Int J Oncol 2009, 35:673-681.
• [37]Zhang J, Liu X, Datta A, Govindarajan K, Tam WL, Han J, George J, Wong C, Ramnarayanan K, Phua TY, et al.: RCP is a human breast cancer-promoting gene with Ras-activating function. J Clin Invest 2009, 119:2171-2183.
• [38]Sadanandam A, Varney ML, Singh S, Ashour AE, Moniaux N, Deb S, Lele SM, Batra SK, Singh RK: High gene expression of semaphorin 5A in pancreatic cancer is associated with tumor growth, invasion and metastasis. Int J Cancer 2010, 127:1373-1383.
• [39]Pan GQ, Ren HZ, Zhang SF, Wang XM, Wen JF: Expression of semaphorin 5A and its receptor plexin B3 contributes to invasion and metastasis of gastric carcinoma. World J Gastroenterol 2009, 15:2800-2804.
• [40]Kamiyama S, Ichimiya T, Ikehara Y, Takase T, Fujimoto I, Suda T, Nakamori S, Nakamura M, Nakayama F, Irimura T, et al.: Expression and the role of 3'-phosphoadenosine 5'-phosphosulfate transporters in human colorectal carcinoma. Glycobiology 2011, 21:235-246.
• [41]Nandan MO, Yoon HS, Zhao W, Ouko LA, Chanchevalap S, Yang VW: Kruppel-like factor 5 mediates the transforming activity of oncogenic H-Ras. Oncogene 2004, 23:3404-3413.
• [42]Liu YL, Yang YM, Xu H, Dong XS: Aberrant expression of USP22 is associated with liver metastasis and poor prognosis of colorectal cancer. J Surg Oncol 2010, 103:283-289.
• [43]Zhang Y, Yao L, Zhang X, Ji H, Wang L, Sun S, Pang D: Elevated expression of USP22 in correlation with poor prognosis in patients with invasive breast cancer. J Cancer Res Clin Oncol 2011, 137:1245-1253.
• [44]Mathupala SP, Ko YH, Pedersen PL: Hexokinase II: cancer’s double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 2006, 25:4777-4786.
• [45]Wen J, Parker BJ, Jacobsen A, Krogh A: MicroRNA transfection and AGO-bound CLIP-seq data sets reveal distinct determinants of miRNA action. RNA 2011, 17:820-834.
• [46]Guo H, Ingolia NT, Weissman JS, Bartel DP: Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010, 466:835-840.
• [47]Warburg O: On respiratory impairment in cancer cells. Science 1956, 124:269-270.
• [48]Vander Heiden MG, Cantley LC, Thompson CB: Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.